Oxidized lipids and lipoproteins: indices of risk or targets for management

Bibliography

• Keys A, Blackburn H, Menotti A et al.: Coronary heart disease in seven countries. Circulation 41(Suppl. 1), 1–211 (1970)
   Google Scholar
• Lipid Research Clinics Program: The LRCCPPT results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251, 365–374 (1984)
   Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cahin-Hemphill L: Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257, 3233–3240 (1987)
   Google Scholar
• Andrews TC, Ballantyne CM, Hsia JA, Kramer-Statin JH: Achieving and maintaining NCEP LDL-cholesterol goal with five statins. Am. J. Med. 111, 185–191 (2001)
   Google Scholar
• Deedwania P, Barter P, Carmena R et al.; for the Treating to New Targets Investigators: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368, 919–928 (2006).
   Google Scholar
• Data from the Treating to New Targets (TNT) study indicating that greater than 40% reduction in LDL-C can be achieved with available statin therapy with minimal side effects.
   Google Scholar
• Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of cardiovascular diseases with statin therapy. Arch. Intern. Med. 166, 2307–2313 (2006)
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-ana lysis. Lancet 371, 117–125 (2008)
   Google Scholar
• Ridker PM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103, 1813–1818 (2001)
   Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286, 64–70 (2001)
   Google Scholar
• Ballantyne M, Hoogeveen RC, Bang H et al.: Lp-PLA2, hsCRP, and risk for incident coronary heart disease in middle aged men and women in the ARIC study. Circulation 109, 837–842 (2004)
   Google Scholar
• Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisenger C: Lp-PLA2 adds to risk prediction of incident coronary events by hsCRP in apparently healthy middle-aged men from the general population from the 14-yr follow-up of a large cohort from southern Germany. Circulation 110, 1903–1908 (2004).
   Google Scholar
• Contribution of inflammation status in the prediction of coronary events. Of interest is the evidence that high-sensitivity C-reactive protein and lipoprotein-associatedphosphlipase A2 (Lp-PLA2) may contribute to residual risk via independent mechanisms.
   Google Scholar
• Steinberg D, Parthasarathy S, Carew TE, Khoo JD, Witztum JL: Beyond cholesterol: modifications of LDL that increase its atherogenicity. N. Engl. J. Med. 320, 915–924 (1989).
   Google Scholar
• Landmark article delineating the evidence in support of the oxidation hypothesis of atherosclerosis.
   Google Scholar
• Hazell LJ, Stocker R: Oxidation of LDL with hypochlorite cause transformation of the lipoprotein into a high-uptake form for macrophages. Biochem. J. 290, 165–172 (1993)
   Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST et al.: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45, 993–1007 (2004).
   Google Scholar
• Review of the evidence in support of the role of oxidized phospholipids in atherosclerosis and the antioxidant properties of HDL.
   Google Scholar
• Avogaro P, Bon Bittolo G, Cazzolato G: Presence of a modified LDL in humans. Arteriosclerosis 8, 79–87 (1988)
   Google Scholar
• Yla-Herttuala S, Palinski W, Rosenfeld ME et al.: Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84, 1086–1095 (1989).
   Google Scholar
• One of the original reports for the presence of a negatively charged form of LDL in atherosclerotic lesions of human subjects with documented coronary artery disease (CAD) and in rabbits with diet-induced atherosclerosis.
   Google Scholar
• Palinski W, Rosenfeld ME, Yla-Herttuala S et al.: LDL undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA 86, 1372–1376 (1989).
   Google Scholar
• Among the first reports demonstrating that oxidative modification of LDL can occur in vivo.
   Google Scholar
• Itabe H, Yamamoto H, Imanaka T et al.: Sensitive detection of oxidatively modified LDL using a monoclonal antibody. J. Lipid Res. 37, 45–53 (1996)
   Google Scholar
• Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscl. Thromb. 14, 32–40 (1994)
   Google Scholar
• Palinski W, Horkko S, Miller E et al.: Cloning of monoclonal antibodies to epitopes of oxidized lipoproteins from ApoE-deficient mice. Demonstration of epitopes of oxidized LDL in human plasma. J. Clin. Invest. 98, 800–814 (1996).
   Google Scholar
• In the ApoE-deficient mouse that is highly susceptible to atherosclerosis, these investigators were able to isolate a number of IgG that recognize epitopes on oxidized human LDL with various affinities.
   Google Scholar
• McEneny J, O’Kane MJ, Moles KW et al.: VLDL subfractions in type II diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia 43, 485–493 (2000)
   Google Scholar
• Mabile L, Salvayre R, Bonnafe M-J, Negre-Salvayre A: Oxidizability and subsequent cytotoxicity of chylomicrons to monocytic U937 and endothelial cells are dependent on dietary fatty acid composition. Free Rad. Biol. Med. 19, 599–607 (1995)
   Google Scholar
• Nakajima K, Nakano T, Tanaka A: The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects of oxidized LDL and remnant lipoproteins in plasma. Clin. Chim. Acta 367, 36–47 (2006).
   Google Scholar
• Reviews evidence to demonstrate that oxidative modification is not limited to plasma LDL. Evidence is presented that triglyceride-rich lipoproteins, including chylomicron remnants, can be oxidized in healthy individuals and, when present at high concentrations, can by cytotoxic just like LDL. The authors raised the possibility that generation of oxidized lipoproteins may be a normal metabolic process and, while they may contribute to disease progression, may not be the initiating cause of disease.
   Google Scholar
• Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381–1478 (2004).
   Google Scholar
• Comprehensive review of the biochemical and physiologic basis of oxidative medications of plasma lipids and proteins.
   Google Scholar
• Le N-A: Reducing oxidized lipids to prevent cardiovascular disease. Curr. Treat. Options Cardiovasc. Med. 10, 263–272 (2008)
   Google Scholar
• Esterbauer H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human LDL. Free Rad. Res. Commun. 6, 67–75 (1989)
   Google Scholar
• Rae TD, Schmidt PJ, Pufahl RA et al.: Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284, 805–808 (1999)
   Google Scholar
• Holvoet P, Donck J, Landeloos M et al.: Correlation between oxidized LDL and von Willebrand Factor in chronic renal failure. Thromb. Haemostasis 76, 663–669 (1996)
   Google Scholar
• Tsimikas S: Measures of oxidative stress. Clin. Lab. Med. 26, 571–590 (2006)
   Google Scholar
• Holvoet P, Kritchevsky SB, Tracy RP et al.: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the Health, Aging, and Body Composition cohort. Diabetes 53, 1068–1073 (2004)
   Google Scholar
• Holvoet P, Lee D-H, Steffes M, Gross M, Jacobs DR Jr: Association between circulating oxidized LDL and incidence of metabolic syndrome. J. Am. Med. Assoc. 299, 2287–2293 (2008).
   Google Scholar
• Evidence for the presence of elevated oxidized (ox)-LDL in individuals with metabolic syndrome, in particular in individuals with abdominal obesity.
   Google Scholar
• Holvoet P, Mertens A, Verhamme P et al.: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease Arterioscl. Thromb. Vasc. Biol. 21, 844–848 (2001)
   Google Scholar
• Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J: Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J. Intern. Med. 256, 413–320 (2004)
   Google Scholar
• Langlois MR, Rietzschel ER, De Buyzere ML, De Bacquer D; the Asklepios Investigators: Femoral plaques confound the association of circulating oxidized LDL with carotid atherosclerosis in a general population aged 35 to 55 years. The Asklepios Study. Arterioscl. Thromb. Vasc. Biol. 28, 1563–1568 (2008)
   Google Scholar
• Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR: The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 194, 245–252 (2007).
   Google Scholar
• Report from the Multi-Ethnic Study of Atherosclerosis (MESA) investigators on the association between ox-LDL levels and conventional risk factors for cardiovascular disease in four different ethnic groups. Subclinical atherosclerosis was assessed by coronary artery calcium score.
   Google Scholar
• Tsimikas S, Brilakis ES, Miller ER et al.: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353, 46–57 (2005).
   Google Scholar
• Elevated concentration of oxidized phospholipids in patients with coronary artery disease. Strong relationship between oxidized phospholipids and Lp(a) observed using this monoclonal antibody.
   Google Scholar
• Tsimikas S, Kiechl S, Willeit J et al.: Oxidized phospholipids predict the presence of carotid and femoral atherosclerosis and symptomatic cardiovascular disease. J. Am. Coll. Cardiol. 47, 2219–2228 (2006).
   Google Scholar
• of high concentrations of oxidized phospholipids in subjects with subclinical atherosclerosis as assessed by carotid intima-media thickness.
   Google Scholar
• Kiechl S, Willeit J, Mayr M et al.: Oxidized phospholipids, Lp(a), Lp-PLA2 activity, and 10-year cardiovascular outcomes. Prospective results from the Bruneck Study. Arterioscl. Thromb. Vasc. Biol. 27, 1788–1795 (2007)
   Google Scholar
• Salonen JT, Yla-Herttuala S, Yamamoto R et al.: Autoantibody against LDL and progression of carotid atherosclerosis. Lancet 339, 883–887 (1992)
   Google Scholar
• Puurunen M, Manttari M, Manninen V et al.: Antibody against oxidized LDL predicting myocardial infarction. Arch. Intern. Med. 154, 2605–2609 (1994)
   Google Scholar
• Bui MN, Sack MN, Moutsatsos G et al.: Autoantibody titers to ox-LDL in patients with coronary atherosclerosis. Am. Heart J. 131, 663–667 (1996)
   Google Scholar
• van de Vijver LPL, Steyger R, van Poppel G et al.: Autoantibodies against mda-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122, 245–253 (1996)
   Google Scholar
• Palinski W, Miller E, Witztum JL: Immunization of LDL receptor-deficient rabbits with homologous malondialdehydemodified LDL reduces atherosclerosis. Proc. Natl Acad. Sci. USA 92, 821–825 (1995).
   Google Scholar
• In the LDL-receptor deficient rabbits, which are highly susceptible to dietinduced atherosclerosis, immunization with malondialdehyde (MDA)-modified LDL prior to the start of atherogenesis was effective in reducing the extent of atherosclerosis.
   Google Scholar
• Ameli S, Hultgardh-Nilsson A, Regnstrom J et al.: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscl. Thomb. Vasc. Biol. 16, 1074–1079 (1996)
   Google Scholar
• Fredrikson GN, Soderberg I, Lindholm M et al.: Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscl. Thromb. Vasc. Biol. 23, 879–884 (2003)
   Google Scholar
• Schiopu A, Frendeus B, Jansson B et al.: Recombinant antibodies to an oxidized LDL epitope induce rapid regression of atherosclerosis in ApoBec-1-/-/LDL receptor-/- mice. J. Am. Coll. Cardiol. 50, 2313–2318 (2007)
   Google Scholar
• Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL: Increased autoantibody titers against epitopes of oxidized LDL in LDL-receptor deficient mice with increased atherosclerosis. Arterioscl. Thromb. Vasc. Biol. 15, 1569–1576 (1995)
   Google Scholar
• Walter MF, Jacob RF, Jeffers B et al.: Serum levels of TBARS predict cardiovascular events in patients with stable coronary artery disease. A longitudinal ana lysis of the PREVENT study. J. Amer. Coll. Cardiol. 44, 1996–2000 (2004)
   Google Scholar
• Salonen JT, Nyyssonen K, Salonen R et al.: Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 95, 840–845 (1997)
   Google Scholar
• Hendrickson A, McKinstry LA, Lewis JK et al.: Ex vivo measures of LDL oxidative susceptibility predict coronary artery disease. Atherosclerosis 179, 147–153 (2005)
   Google Scholar
• Rabini RA, Tesei M, Galeazzi T, Dousset N, Ferretti G, Mazzanti L: Increased susceptibility to peroxidation of VLDL from non-insulin-dependent diabetic patients: a possible correlation with fatty acid composition. Mol. Cell. Biochem. 199, 63–67 (1999)
   Google Scholar
• McEneny J, O’Kane MJ, Moles KW et al.: Very low density lipoprotein subfractions in Type 2 diabetes mellitus: Alterations in composition and susceptibility to oxidation. Diabetologia 43, 485–493 (2000)
   Google Scholar
• Ryglewicz D, Rodo M, Roszczynko M et al.: Dynamics of LDL oxidation in ischemic stroke patients. Acta Neurol. Scand. 105, 185–188 (2002)
   Google Scholar
• Tribblbe DL, Holl LG, Wood PD, Krauss RM: Variations in oxidative susceptibility among six LDL subfractions of differing density and particle size. Atherosclerosis 93, 189–199 (1992)
   Google Scholar
• Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM: Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense LDL. Am. J. Med. 110, 103–110 (2001)
   Google Scholar
• Rudel LL, Shah R, Greene DG: Study of the atherogenic dyslipidemia induced by dietary cholesterol in rhesus monkeys (Macaca mulatta). J. Lipid Res. 20, 55–65 (1979)
   Google Scholar
• Le N-A, Li X, Kyung S, Brown WV: Evidence for the in vivo generation of oxidatively modified epitopes in patients with documented CAD. Metabolism 49, 1271–1277 (2000).
   Google Scholar
• Titers of circulating autoantibodies against MDA-modified LDL can be reduced transiently in patients with documented CAD within 2–4 h of consumption of a fat-containing shake. Similar reductions were not observed in healthy, young subjects with normal lipids and no previous history of cardiovascular disease.
   Google Scholar
• Gradek Q, Harris M, Yahia N, Davis W, Le N-A, Brown WV: Polyunsaturated fatty acids acutely suppress antibodies to malondialdehyde-modified LDL in patients with vascular disease. Am. J. Cardiol. 93, 881–885 (2004).
   Google Scholar
• Acute reduction in titers of circulating antibodies against MDA-LDL observed in patients with cardiovascular disease is specific for test meal enriched in polyunsaturated fatty acids, which are more susceptible to oxidation. Similar changes were not demonstrated when these patients were challenged with test meals enriched in monounsaturated or saturated fatty acids. Reduction in antibody titers was not observed during an oral glucose tolerance test.
   Google Scholar
• Louheranta AM, Porkkala-Sarataho EK, Nyyssonen MK, Salonen RM, Salonen JT: Linoleic acid intake and susceptibility of very-low-density and low-density lipoproteins to oxidation in men. Am. J. Clin. Nutr. 63, 698–703 (1996)
   Google Scholar
• Ceriello A, Ruggle JA, Piconi L et al.: Effects of pramlitide on postprandial glucose excursion and measures of oxidative stress in patients with Type 1 diabetes. Diabetes Care 28, 632–637 (2005)
   Google Scholar
• Ceriello A, Lush CW, Darsow T et al.: Pramlitide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. Diab. Metab. Res. Rev. 24, 103–108 (2008).
   Google Scholar
• Administration of pramlitide to reduce postprandial hyperglycemia in patients with Type 2 diabetes mellitus is associated with significant reductions in meal-induced changes in oxidative markers, including ox-LDL.
   Google Scholar
• Tsimikas S, Bermark C, Beyer RW et al.: Temporal increases in plasma markers of oxidized LDL strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol. 41, 360–370 (2003)
   Google Scholar
• Tsimikas S, Lau HK, Han K-R et al.: Percutaneous coronary intervention results in acute increases in oxidized phospholipids and Lp(a). Short-term and long-term immunologic responses to ox-LDL. Circulation 109, 3164–3170 (2004)
   Google Scholar
• Sawamura T, Kume N, Aoyama T et al.: An endothelial receptor for oxidized LDL. Nature 386, 73–77 (1997)
   Google Scholar
• Endemann G, Stanton IW, Madden KS, Bryant CM, White RT, Protter AA: CD36 is a receptor for oxidized LDL. J. Biol. Chem. 268, 11811–11816 (1993)
   Google Scholar
• Acton SL, Sherer PE, Lodish HF, Krieger M: Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269, 21003–21009 (1994)
   Google Scholar
• Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D: Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized LDL. Proc. Natl Acad. Sci. USA 93, 14833–14838 (1996)
   Google Scholar
• Sun B, Boyanovsky BB, Connelly MA et al.: Distinct mechanisms for ox-LDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI. J. Lipid Res. 48, 2560–2570 (2007)
   Google Scholar
• WIklundm O, Witztum JL, Carew TE, Pitman RC, Elam RL, Steinberg D: Turnover and tissue sites of degradation of glucosylated LDL in normal and immunized rabbits. J. Lipid Res. 28, 1098–1109 (1987)
   Google Scholar
• Torzewski M, Shaw PX, K-Han R et al.: Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscl. Thromb. Vasc. Biol. 24, 2307–2312 (2004).
   Google Scholar
• Reductions in the uptake of radiolabeled antibodies specific for oxidized epitopes following risk-reduction interventions would suggest that the composition of the atherosclerotic plaques may have been altered.
   Google Scholar
• Briley-Saebo KC, Shaw PX, Mulder WJ et al.: Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 117, 3206–3215 (2008)
   Google Scholar
• Tsmikas S, Shortal BP, Witztum JL, Palinski W: In vivo uptake of radiolabeled MDA2, an oxidation specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscl. Thromb. Vasc. Biol. 20, 689–697 (2000)
   Google Scholar
• Nishi K, Itabe H, Uno M et al.: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscl. Thromb. Vasc. Biol. 22, 1649–1654 (2002)
   Google Scholar
• Tsimikas S, Aikawa M, Miller FJ Jr et al.: Increased plasma oxidized phospholipid: ApoB-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscl. Thromb. Vasc. Biol. 27, 175–181 (2007).
   Google Scholar
• Following lipid-lowering interventions, significant reductions in oxidized phospholipids in the arterial wall were observed. Plasma levels of oxidized phospholipids, however, were increased. This finding was unexpected as the working hypothesis was that oxidized plasma levels of oxidized phospholipids are proatherogenic and interventions that are efficacious in reducing risk should reduce the levels of oxidized phospholipids.
   Google Scholar
• Ishigaki Y, Katagiri H, Gao J et al.: Impact of plasma ox-LDL removal on atherosclerosis. Circulation 118, 75–83 (2008).
   Google Scholar
• Overexpression of a scavenger receptor specific for ox-LDL is associated with reduction in atherosclerotic disease severity in mice.
   Google Scholar
• Ky B, Burke A, Tsimikas S et al.: The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J. Am. Coll. Cardiol. 51, 1653–1662 (2008)
   Google Scholar
• Choi SY, Chae A, Miller E et al.: Relationship between biomarkers of oxidized LDL, statin therapy, quantitative coronary angiography, and atheroma volume. J. Am. Coll. Cardiol. 52, 24–32 (2008)
   Google Scholar
• Esposito K, Giugliano D, Nappo F, Marfella R; for the Campanian Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation 110, 214–219 (2004)
   Google Scholar
• EC Tozer, Carew TE: Residence time of LDL in the normal and atherosclerotic rabbit aorta. Circulation Res. 80, 208–218 (1997).
   Google Scholar